---
title: "Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Access and distribution"
description: "Formulary evidence on Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Access and distribution. Topics: Access during development: clinical trial participation only, Commercial manufacturing and supply agreement with Catalent, Commercial-scale manufacturing process qualification, Care setting: intrathecal administration with outpatient potential, and 2 further topics. 6 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description/access-and-distribution"
published: "2026-11-15T20:23:41-05:00"
modified: "2026-11-15T20:23:41-05:00"
---

# Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Access and distribution

<a id="heading-2.1.2.11"></a>

## 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

### Access during development: clinical trial participation only

> “Access to Taysha’s investigational products is currently available only through participation in a clinical trial for patients who meet the applicable eligibility criteria. At this stage of development, Taysha does not offer *Expanded Access to its investigational therapies.”

Source: [Taysha Gene Therapies healthcare professionals page](https://tayshagtx.com/healthcare-professionals/)

<a id="topic-2.1.2.11-2"></a>

### Commercial manufacturing and supply agreement with Catalent

> “Building on a partnership that has supported the development of TSHA-102 since 2020, the agreement secures long-term commercial manufacturing capacity and a scalable supply framework to support a potential commercial launch and future demand.”
> “Catalent will provide GMP manufacturing and commercial supply of TSHA-102 at its FDA-licensed commercial gene therapy facility in Harmans, Maryland, leveraging its experience across more than 90 gene therapy programs, including multiple commercial products.”

Source: [Taysha Gene Therapies Catalent commercial manufacturing announcement (2026)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-and-catalent-expand-strategic-partnership)

<a id="topic-2.1.2.11-3"></a>

### Commercial-scale manufacturing process qualification

> “Completed BLA-Enabling Process Performance Qualification (PPQ) Campaign for TSHA-102.”
> “The final TSHA-102 commercial manufacturing process consistently achieved a single-digit empty capsid percentage, an important indicator of product quality that contributes to patient safety. The PPQ results also demonstrate the process consistency and scalability required to support potential commercial demand.”

Source: [Taysha Gene Therapies third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456974/d497108dex991.htm)

<a id="topic-2.1.2.11-4"></a>

### Care setting: intrathecal administration with outpatient potential

> “TSHA-102 delivered intrathecally, a minimally invasive procedure with outpatient potential, enabling broad, scalable access”

Source: [Taysha Gene Therapies June 2026 program update presentation (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526276738/d20817dex992.htm)

<a id="topic-2.1.2.11-5"></a>

### Market access and payer research

> “Completed payer research to inform market access planning, which demonstrated strong support for TSHA-102’s significant value proposition and reimbursement potential, including:”
> “TSHA-102 was viewed as a high-value therapy due to its transformative disease-modifying potential in a population with high unmet need, combined with the convenience of a one-time IT administration that can be performed in an outpatient setting”
> “Strong efficacy, safety and durability are expected to drive coverage and reimbursement, with durable functional benefits serving as the key value determinant in this high unmet need setting”

Source: [Taysha Gene Therapies second quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526344594/d161230dex991.htm)

<a id="topic-2.1.2.11-6"></a>

### Commercial inventory build

> “Company raised an additional $50.0 million in gross proceeds by utilizing its at-the-market equity offering program, with proceeds intended to support a potential commercial inventory build in 2027.”

Source: [Taysha Gene Therapies full-year 2025 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115177/d46409dex991.htm)

## Related pages
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Terms and abbreviations](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations.md)
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Product information and disease description](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Clinical evidence](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Economic information and modeling report](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: References](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references.md)
